X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (173382) 173382
Book Review (33484) 33484
Publication (11529) 11529
Newsletter (11298) 11298
Newspaper Article (2328) 2328
Magazine Article (565) 565
Conference Proceeding (554) 554
Book Chapter (335) 335
Book / eBook (288) 288
Transcript (136) 136
Trade Publication Article (84) 84
Dissertation (72) 72
Web Resource (27) 27
Reference (16) 16
Paper (11) 11
Presentation (11) 11
Data Set (7) 7
Streaming Video (5) 5
Journal / eJournal (4) 4
Report (4) 4
Government Document (2) 2
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (159202) 159202
humans (147557) 147557
female (79613) 79613
oncology (67787) 67787
male (66637) 66637
cancer (59009) 59009
middle aged (52029) 52029
animals (47910) 47910
aged (44659) 44659
chemotherapy (43389) 43389
antineoplastic agents - administration & dosage (42115) 42115
adult (40999) 40999
antineoplastic agents - therapeutic use (39732) 39732
antineoplastic agents (36453) 36453
antineoplastic combined chemotherapy protocols - therapeutic use (33583) 33583
antimitotic agents (32811) 32811
treatment outcome (29051) 29051
care and treatment (28854) 28854
mice (26286) 26286
pharmacology & pharmacy (25245) 25245
antineoplastic agents - pharmacology (24503) 24503
antineoplastic agents - adverse effects (21319) 21319
research (21291) 21291
cell line, tumor (20470) 20470
neoplasms - drug therapy (17655) 17655
therapy (16370) 16370
analysis (15193) 15193
health aspects (14449) 14449
apoptosis (14442) 14442
aged, 80 and over (14379) 14379
drug therapy (14374) 14374
medicine & public health (14245) 14245
dose-response relationship, drug (13996) 13996
tumors (13717) 13717
breast neoplasms - drug therapy (13688) 13688
hematology (12992) 12992
antineoplastic combined chemotherapy protocols - adverse effects (12873) 12873
drug administration schedule (12564) 12564
combined modality therapy (12194) 12194
prognosis (11567) 11567
breast cancer (11338) 11338
lung neoplasms - drug therapy (11181) 11181
cisplatin (11043) 11043
apoptosis - drug effects (10657) 10657
metastasis (10613) 10613
cisplatin - administration & dosage (10572) 10572
retrospective studies (10473) 10473
abridged index medicus (10445) 10445
antineoplastic combined chemotherapy protocols - administration & dosage (10127) 10127
neoplasm staging (10117) 10117
disease-free survival (10059) 10059
rats (9503) 9503
time factors (9475) 9475
drugs (9409) 9409
survival (9404) 9404
carcinoma (9085) 9085
hematology, oncology and palliative medicine (8882) 8882
adolescent (8881) 8881
survival rate (8748) 8748
doxorubicin - administration & dosage (8684) 8684
cell proliferation - drug effects (8677) 8677
expression (8584) 8584
dosage and administration (8538) 8538
survival analysis (8392) 8392
oncology, experimental (8304) 8304
clinical trials (8238) 8238
trial (8105) 8105
antineoplastic agents - pharmacokinetics (7978) 7978
fluorouracil - administration & dosage (7886) 7886
paclitaxel (7872) 7872
surgery (7866) 7866
article (7863) 7863
clinical trials as topic (7672) 7672
mice, nude (7666) 7666
toxicity (7628) 7628
cells (7579) 7579
antineoplastic agents - chemistry (7572) 7572
follow-up studies (7562) 7562
drug delivery systems (7447) 7447
in-vitro (7350) 7350
radiotherapy (7210) 7210
doxorubicin (7161) 7161
paclitaxel - administration & dosage (7125) 7125
cell survival - drug effects (7111) 7111
drug therapy, combination (7059) 7059
risk factors (6957) 6957
cancer therapies (6917) 6917
breast neoplasms - pathology (6896) 6896
xenograft model antitumor assays (6861) 6861
antineoplastic agents, phytogenic - administration & dosage (6839) 6839
biochemistry & molecular biology (6718) 6718
breast-cancer (6695) 6695
child (6491) 6491
carcinoma, non-small-cell lung - drug therapy (6487) 6487
pharmacokinetics (6437) 6437
deoxycytidine - analogs & derivatives (6364) 6364
neoplasm metastasis (6242) 6242
chemotherapy, adjuvant (6229) 6229
cyclophosphamide - administration & dosage (6205) 6205
medical research (6040) 6040
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Gerstein Science - Stacks (184) 184
Online Resources - Online (31) 31
Sunnybrook Health Sciences Centre - Sunnybrook Stacks (18) 18
Collection Dvlpm't (Acquisitions) - Vendor file (16) 16
Collection Dvlpm't (Acquisitions) - Closed Orders (11) 11
Chemistry (A D Allen) - Stacks (3) 3
Credit Valley Hospital - Stacks (2) 2
Gerstein Science - Circulation Desk (2) 2
Scarborough Hospital - Birchmount (2) 2
Earth Sciences (Noranda) - Stacks (1) 1
East Asian (Cheng Yu Tung) - Reference (1) 1
Gerstein Science - Reference (1) 1
Lakeridge Health Sciences - Online (1) 1
Lakeridge Health Sciences - Oshawa (1) 1
Scarborough Hospital - General (1) 1
Scarborough Hospital - Sunnybrook Stacks (1) 1
St. Michael's Hospital - Stacks (1) 1
Sunnybrook Health Sciences Centre - Online (1) 1
Sunnybrook Health Sciences Centre - Oshawa (1) 1
Sunnybrook Health Sciences Centre - Sunnybrook Reference (1) 1
UTL at Downsview - May be requested (1) 1
UofT at Mississauga - Stacks (1) 1
UofT at Scarborough - Stacks (1) 1
West Park Healthcare Centre - Stacks (1) 1
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (177175) 177175
Japanese (3976) 3976
French (1503) 1503
German (1486) 1486
Chinese (1018) 1018
Russian (950) 950
Italian (465) 465
Spanish (412) 412
Polish (285) 285
Hungarian (183) 183
Czech (110) 110
Dutch (110) 110
Danish (89) 89
Swedish (72) 72
Norwegian (54) 54
Portuguese (41) 41
Ukrainian (38) 38
Hebrew (37) 37
Romanian (24) 24
Korean (19) 19
Serbian (19) 19
Bulgarian (17) 17
Finnish (17) 17
Croatian (15) 15
Lithuanian (14) 14
Turkish (11) 11
Slovak (10) 10
Bosnian (1) 1
Greek (1) 1
Kurdish (1) 1
Slovenian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


2011, 8th ed., ISBN 160831782X, xiv, 875
Skeel's Handbook of Cancer Chemotherapy combines in one place the most current rationale and specific details necessary to safely administer chemotherapy for... 
Chemotherapy | Cancer | Handbooks, manuals, etc
Book
2011, 8th ed., ISBN 160831782X, xiv, 875
Skeel's Handbook of Cancer Chemotherapy combines in one place the most current rationale and specific details necessary to safely administer chemotherapy for... 
Chemotherapy | Cancer | Handbooks, manuals, etc
Book
The New England Journal of Medicine, ISSN 0028-4793, 01/2016, Volume 374, Issue 4, pp. 311 - 322
An oral inhibitor of BCL2 produces substantial responses in the majority of patients with refractory chronic lymphocytic leukemia. The agent is so effective... 
DOSE-ESCALATION | APOPTOSIS | MEDICINE, GENERAL & INTERNAL | CLL | INTERNATIONAL WORKSHOP | CYCLOPHOSPHAMIDE | RITUXIMAB | IBRUTINIB | INHIBITOR | PHASE-I | FLUDARABINE | Recurrence | Humans | Middle Aged | Male | Bridged Bicyclo Compounds, Heterocyclic - administration & dosage | Antineoplastic Agents - administration & dosage | Remission Induction | Sulfonamides - pharmacokinetics | Dose-Response Relationship, Drug | Disease-Free Survival | Bridged Bicyclo Compounds, Heterocyclic - adverse effects | Tumor Lysis Syndrome - etiology | Antineoplastic Agents - adverse effects | Aged, 80 and over | Sulfonamides - adverse effects | Adult | Female | Proto-Oncogene Proteins c-bcl-2 - antagonists & inhibitors | Aged | Antineoplastic Agents - pharmacokinetics | Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy | Sulfonamides - administration & dosage | Bridged Bicyclo Compounds, Heterocyclic - pharmacokinetics | Antimitotic agents | Treatment outcome | Care and treatment | Usage | Safety and security measures | Lymphocytic leukemia | Analysis | Clinical trials | Dosage and administration | Antineoplastic agents | Pharmacokinetics | Risk factors | Flow cytometry | Chronic lymphatic leukemia | Cell survival | Leukemia | Minimal residual disease | Diarrhea | Chromosome deletion | Nausea | Lymphatic leukemia | Lymphoma | Patients | Proteins | Chemotherapy | Fludarabine | Clonal deletion | Lysis | Respiratory tract diseases | Lymphomas | Chromosome 17 | Neutropenia | Apoptosis | Index Medicus | Abridged Index Medicus
Journal Article
Lancet, The, ISSN 0140-6736, 2016, Volume 387, Issue 10032, pp. 2008 - 2016
Journal Article
Journal of the American Chemical Society, ISSN 0002-7863, 11/2013, Volume 135, Issue 46, pp. 17617 - 17629
Journal Article
Lancet, The, ISSN 0140-6736, 2015, Volume 387, Issue 10027, pp. 1540 - 1550
Summary Background Despite recent advances in the treatment of advanced non-small-cell lung cancer, there remains a need for effective treatments for... 
Internal Medicine | CRITERIA | MEDICINE, GENERAL & INTERNAL | ANTI-PD-L1 ANTIBODY | THERAPY | NSCLC | IMMUNOTHERAPY | PD-L1 | BLOCKADE | NIVOLUMAB | CHEMOTHERAPY | Lung Neoplasms - drug therapy | Carcinoma, Non-Small-Cell Lung - chemistry | Humans | Middle Aged | Gene Expression Regulation, Neoplastic | Lung Neoplasms - pathology | Male | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - administration & dosage | Molecular Targeted Therapy | Patient Selection | Taxoids - therapeutic use | Antibodies, Monoclonal, Humanized - administration & dosage | Antineoplastic Agents - adverse effects | Adult | Female | Taxoids - adverse effects | Carcinoma, Non-Small-Cell Lung - pathology | Antibodies, Monoclonal, Humanized - adverse effects | Antibodies, Monoclonal, Humanized - therapeutic use | Drug Administration Schedule | Lung Neoplasms - chemistry | Kaplan-Meier Estimate | Treatment Outcome | Disease-Free Survival | Taxoids - administration & dosage | Aged | B7-H1 Antigen - analysis | Carcinoma, Non-Small-Cell Lung - drug therapy | Antimitotic agents | Medical colleges | Lung cancer, Non-small cell | Antineoplastic agents | Analysis | Chemotherapy | Biopsy | Genes | Lung cancer | Clinical trials | Oncology | Mutation | Tumors | Slopes | Cell survival | Medical treatment | Medical services | FDA approval | Survival | Patients | Medical centres | Pembrolizumab | Randomization | Interactive systems | Immunotherapy | Risk assessment | PD-L1 protein | Biomarkers | Index Medicus | Abridged Index Medicus
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 01/2016, Volume 374, Issue 4, pp. 323 - 332
Acalabrutinib is an irreversible inhibitor of Bruton's tyrosine kinase with greater specificity for the enzyme than the first-in-class agent, ibrutinib. It had... 
B-CELL RECEPTOR | MEDICINE, GENERAL & INTERNAL | ACTIVATION | IN-VIVO | X-LINKED AGAMMAGLOBULINEMIA | IBRUTINIB | BTK | PCI-32765 | TYROSINE KINASE INHIBITOR | LYMPHOMA | OPEN-LABEL | Recurrence | Benzamides - pharmacokinetics | Humans | Middle Aged | Pyrazines - administration & dosage | Male | Antineoplastic Agents - administration & dosage | Leukemia, Lymphocytic, Chronic, B-Cell - genetics | Protein Kinase Inhibitors - adverse effects | Diarrhea - chemically induced | Dose-Response Relationship, Drug | Benzamides - administration & dosage | Antineoplastic Agents - adverse effects | Female | Antineoplastic Agents - pharmacokinetics | Benzamides - adverse effects | Headache - chemically induced | Chromosome Deletion | Protein Kinase Inhibitors - pharmacokinetics | Administration, Oral | Disease-Free Survival | Protein Kinase Inhibitors - administration & dosage | Agammaglobulinaemia Tyrosine Kinase | Pyrazines - pharmacokinetics | Pyrazines - adverse effects | Aged | Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy | Protein-Tyrosine Kinases - antagonists & inhibitors | Antimitotic agents | Treatment outcome | Usage | Care and treatment | Safety and security measures | Lymphocytic leukemia | Analysis | Clinical trials | Pharmacology | Dosage and administration | Pharmacokinetics | Antineoplastic agents | Tyrosine | Headache | Pharmacodynamics | Transformation | Chronic lymphatic leukemia | Inhibitor drugs | Leukemia | Diarrhea | Chromosome deletion | Lymphatic leukemia | Kinases | Lymphoma | Bruton's tyrosine kinase | Patients | Clonal deletion | Lymphomas | Safety | Drug therapy | Lymphocytosis | Protein-tyrosine kinase | Chromosome 17 | Index Medicus | Abridged Index Medicus
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 04/2012, Volume 30, Issue 10, pp. 1122 - 1128
Journal Article
Science, ISSN 0036-8075, 5/2010, Volume 328, Issue 5981, pp. 1031 - 1035
Poor penetration of anticancer drugs into tumors can be an important factor limiting their effícacy. We studied mouse tumor models to show that a previously... 
Molecules | Intravenous injections | Medical treatment | REPORTS | Antineoplastics | Antibodies | Liposomes | Dosage | Prostate cancer | Tumors | Cancer | NANOPARTICLES | INTEGRINS | MULTIDISCIPLINARY SCIENCES | MOUSE MODEL | IN-VIVO | DOXORUBICIN | PHAGE DISPLAY | VASCULAR-PERMEABILITY FACTOR | CELL | ENDOTHELIAL GROWTH-FACTOR | DELIVERY | Neoplasms - metabolism | Doxorubicin - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Neuropilin-1 - metabolism | Albumin-Bound Paclitaxel | Humans | Antineoplastic Combined Chemotherapy Protocols - pharmacokinetics | Capillary Permeability - drug effects | Antibodies, Monoclonal - therapeutic use | Antineoplastic Agents - therapeutic use | Paclitaxel - pharmacokinetics | Antineoplastic Agents - administration & dosage | Albumins - therapeutic use | Antibodies, Monoclonal, Humanized | Antineoplastic Agents - pharmacokinetics | Paclitaxel - administration & dosage | Doxorubicin - administration & dosage | Oligopeptides - pharmacokinetics | Antibodies, Monoclonal - pharmacokinetics | Albumins - administration & dosage | Neoplasms - blood supply | Oligopeptides - metabolism | Permeability | Paclitaxel - therapeutic use | Doxorubicin - pharmacokinetics | Neoplasms - drug therapy | Xenograft Model Antitumor Assays | Albumins - pharmacokinetics | Animals | Antibodies, Monoclonal - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Mice | Oligopeptides - administration & dosage | Oligopeptides - pharmacology | Trastuzumab | Antimitotic agents | Peptides | Research | Antineoplastic agents | Drug therapy | Health aspects | Chemotherapy | Index Medicus | Drugs | Nanoparticles | Side effects | Doxorubicin | Constraining
Journal Article
Lancet, The, ISSN 0140-6736, 2012, Volume 379, Issue 9829, pp. 1893 - 1901
Summary Background Dabrafenib is an inhibitor of BRAF kinase that is selective for mutant BRAF. We aimed to assess its safety and tolerability and to establish... 
Internal Medicine | SURVIVAL | IRRADIATION | MEDICINE, GENERAL & INTERNAL | PATHWAY | RAF INHIBITOR RESISTANCE | B-RAF | MUTATIONS | CANCER | BRAF(V600E) | VEMURAFENIB | Oximes - adverse effects | Humans | Middle Aged | Carcinoma, Squamous Cell - chemically induced | Oximes - administration & dosage | Imidazoles - administration & dosage | Male | Fatigue - chemically induced | Antineoplastic Agents - administration & dosage | Fever - chemically induced | Indoles - administration & dosage | Brain Neoplasms - secondary | Neoplasms - genetics | Antineoplastic Agents - adverse effects | Melanoma - genetics | Adult | Female | Drug Administration Schedule | Imidazoles - adverse effects | Genotype | Treatment Outcome | Skin Neoplasms - chemically induced | Brain Neoplasms - drug therapy | Mutation - genetics | Melanoma - secondary | Neoplasms - drug therapy | Proto-Oncogene Proteins B-raf - antagonists & inhibitors | Maximum Tolerated Dose | Indoles - adverse effects | Proto-Oncogene Proteins B-raf - genetics | Melanoma - drug therapy | Sulfonamides - adverse effects | Sulfonamides - administration & dosage | Antimitotic agents | Complications and side effects | Melanoma | Dosage and administration | Metastasis | Antineoplastic agents | Drug therapy | Clinical trials | Medical research | Chemotherapy | Mutation | Toxicity | Tumors | Index Medicus | Abridged Index Medicus
Journal Article